Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Though scientific trials depend on bodily places (websites) the place contributors journey to obtain therapy, comparatively little is understood concerning the total...
Dr. Vinayak Venkataraman, medical oncologist and director of Sarcoma Pathways at Dana-Farber Most cancers Institute in Boston, lately sat down with CURE...
